<DOC>
	<DOC>NCT01144728</DOC>
	<brief_summary>Primary Objective: - To describe the conditions of initiation and titration of Amaryl M, according to previous treatment: - initial dose - titration scheme - efficacy after 4 months assessed by HbA1C - tolerability (number and severity of hypoglycaemia) Secondary Objective: - Fasting Plasma Glucose - Weight evolution</brief_summary>
	<brief_title>Initiation and Titration of Amaryl</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria: Patients with Type 2 diabetes who have been treated with a stable dose (any dose) of : sulfonylurea monotherapy or metformin monotherapy or free combination of glimepiride and metformin with a stable dose (any dose) Body Mass Index (BMI) between 20 and 40 kg/m2 HbA1c superior or egal to 7.5% FPG superior or egal 7 mmol/l Exclusion criteria: Secondary or insulindependant diabetes Any severe chronic disease (hepatic, renal impairments) History of major cardiovascular event in the last 6 months Acute conditions with the potential to alter renal function such as: dehydratation, severe infection, shock, IV administration of iodinated contrast agents Allergy to sulfonylurea, metformin Drug or alcohol abuse Pregnancy, lactation The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>